Global healthcare giant Roche has struck a definitive merger agreement to acquire US-based AI pathology company PathAI, accelerating its push into digital diagnostics and AI-powered clinical decision support.

 

The deal builds on an existing partnership launched in 2021 and expanded in 2024 to co-develop AI-enabled companion diagnostic algorithms. Once completed—expected in the second half of 2026—PathAI will be folded into Roche’s Diagnostics division, pending regulatory and antitrust approvals.

 

The acquisition positions Roche more aggressively in digital pathology, a field rapidly replacing manual lab workflows with automated, AI-driven analysis of high-resolution tissue imaging. 

 

The technology enables pathologists to analyse digitised biopsy samples faster and with enhanced precision, supporting quicker clinical decisions for patients.

 

“Digital pathology has the potential to improve precision diagnosis of cancer and enable physicians to offer better tailored treatment regimens,” said Matt Sause, CEO of Roche Diagnostics. 

 

“Bringing PathAI into Roche Diagnostics will allow us to combine their best-in-class digital pathology tools with our leading oncology diagnosis platforms to deliver better insights for physicians and potentially better outcomes for patients worldwide.”

 

PathAI leadership framed the deal as a global scaling opportunity for its AI platform.

 

Andy Beck, CEO and Co-Founder of PathAI, adds: “Joining forces with Roche marks a new era for PathAI, enabling us to realise our mission of improving patient outcomes through AI-powered pathology at unprecedented scale and speed. Roche's global infrastructure and expertise will bring our digital diagnostics technology to patients worldwide.”

 

At the centre of PathAI’s offering is AISight IMS, a digital pathology workflow and analytics platform designed to streamline lab operations while embedding AI-driven insights directly into diagnostic processes. Roche plans to scale the platform globally across its diagnostics footprint.

 

Beyond clinical diagnostics, Roche is also betting on expanded capabilities in biopharma services. PathAI’s AI tools—used in clinical trial support, translational research, and biomarker discovery—are expected to strengthen Roche’s companion diagnostics and drug development ecosystem, potentially accelerating identification of new drug targets and diagnostic tools.

 

Financially, the agreement includes a USD 750 million upfront payment, with up to an additional USD 300 million tied to milestone achievements.